Eli Lilly and Company (NYSE:LLY) Rating Increased to Hold at Hsbc Global Res

Key Points

• Eli Lilly and Company has been upgraded to a "hold" rating by Hsbc Global Res, reflecting a shift in market perception of the stock.
• Despite mixed ratings from other analysts, the company's consensus rating remains a "Moderate Buy" with a target price of $950.17.
• In its latest earnings report, Eli Lilly reported $6.31 EPS, surpassing estimates by $0.72, and showed a 37.6% year-over-year revenue increase.

Hsbc Global Res upgraded shares of Eli Lilly and Company (NYSE:LLY - Free Report) from a moderate sell rating to a hold rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

A number of other brokerages have also weighed in on LLY. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research note on Sunday, August 17th. HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and raised their price target for the company from $675.00 to $700.00 in a research note on Wednesday. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Cantor Fitzgerald decreased their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Finally, Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $950.17.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $0.45 during midday trading on Wednesday, reaching $732.41. The company had a trading volume of 2,548,350 shares, compared to its average volume of 6,895,566. The company has a market capitalization of $693.20 billion, a P/E ratio of 47.87, a P/E/G ratio of 1.02 and a beta of 0.44. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $969.65. The firm's fifty day simple moving average is $748.68 and its 200-day simple moving average is $785.49. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company's stock.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently added to or reduced their stakes in the stock. WestEnd Advisors LLC increased its holdings in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $27,000. Evolution Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $29,000. Finally, Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $31,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.